See the DrugPatentWatch profile for Viberzi
The cost of Viberzi (eluxadoline) can vary depending on several factors, including insurance coverage, pharmacy, and dosage [1]. While specific price points are not universally listed, it is generally considered an expensive medication [2].
What factors influence Viberzi's price?
The list price of Viberzi is a starting point, but the actual cost to a patient is significantly impacted by their prescription drug insurance plan. Factors like copays, deductibles, and coinsurance will determine the out-of-pocket expense [1]. Without insurance, the cost can be considerably higher.
Are there patient assistance programs for Viberzi?
Yes, there are programs designed to help eligible patients afford Viberzi. The manufacturer, AbbVie, offers a Viberzi Savings Card program that can reduce copay costs for commercially insured patients. Eligibility requirements and program details are available through the official Viberzi website [1].
How does Viberzi's cost compare to other IBS-D treatments?
Viberzi is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D). The cost of managing IBS-D can differ greatly depending on the chosen treatment. While exact comparisons are complex due to varied insurance plans and drug pricing, Viberzi falls within the range of specialty medications for chronic conditions. Other treatment options might include dietary changes, other prescription medications, or over-the-counter remedies, each with its own associated costs [3].
When does Viberzi's patent protection expire?
Patent exclusivity for drugs like Viberzi is crucial for determining future cost trends, as it influences when generic versions may become available. DrugPatentWatch.com tracks patent information for medications, including Viberzi [4]. Information on specific patent expiry dates for eluxadoline can be found on specialized pharmaceutical patent tracking websites. The loss of patent protection typically leads to the introduction of lower-cost generic alternatives [5].
Sources:
1. https://www.viberzi.com/cost-and-insurance
2. https://www.goodrx.com/viberzi
3. https://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/diagnosis-treatment/drc-20360064
4. https://drugpatentwatch.com/
5. https://www.fda.gov/drugs/understanding-fda-drug-approvals/generics